Core Insights - Novavax has received FDA approval for its Covid-19 vaccine, Nuvaxovid, after a delay, but with specific usage restrictions for certain age groups [2][4] - The approval reflects skepticism within federal health agencies regarding vaccines, particularly from appointed leaders [3] - Novavax must conduct additional studies to assess potential links between its vaccine and heart conditions, such as myocarditis [6][7] Group 1: FDA Approval and Restrictions - The FDA approved Novavax's Covid-19 vaccine, limiting its use to individuals aged 65 and older and those aged 12 to 64 with underlying health conditions [2][4] - The approval comes after the vaccine was previously used under emergency authorization since 2022 [4] Group 2: Market Position and Partnerships - Novavax is preparing for commercial delivery of its vaccine in the U.S. this fall, in partnership with Sanofi, following a $1.2 billion licensing deal [8] - The partnership with Sanofi is expected to enhance Novavax's market share in the Covid vaccine sector due to Sanofi's strong distribution capabilities [8] Group 3: Financial Implications - The full approval has triggered a $175 million milestone payment to Novavax from Sanofi, which is significant for the company [9] - Analysts suggest that the narrower approval may not be detrimental, as the 65 and older age group represents a substantial portion of the Covid vaccination demographic [9]

Company Overview - Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform [3] - The company's vaccines are designed to be administered in pill form, which can be stored and shipped without refrigeration, thus eliminating the risk of needle-stick injuries [3] Leadership Change - Jeroen Grasman has been appointed as the Chief Financial Officer (CFO) of Vaxart, effective May 19, 2025, succeeding Phillip Lee, who is resigning for personal reasons [1][2] - Mr. Grasman brings over 20 years of financial leadership experience in the biotech sector, having previously served as CFO at AltruBio and held senior positions at PACT Pharma and Intarcia Therapeutics [2] Strategic Focus - The company aims to advance its oral pill vaccine programs, leveraging Mr. Grasman's extensive financial expertise and operational acumen [2] - Vaxart's development pipeline includes vaccines targeting coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [3]

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Tuesday, ...

SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced that members of the management team will present at the Citizens Life Sciences conference taking place May 7-8, 2025. Presentation Details:Date and Time: Wednesday, May 7 at 1:00 PM ETWebcast: Click Here A live webcast will be available on the Company’s website at www.vaxart.com, and a replay of the presentation will be available for 30 days following the conclusion of the event. Institutional investo ...